CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer’s Disease
Cells · 2023
DOI: 10.3390/cells12091287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Tatiana Brustovetsky und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill Drive, Medical Science Building, Room 362, Indianapoli…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NINDS NIH HHS, NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Mitochondrial bioenergetics and dynamics (alterations in morphology and motility of mitochondria) play critical roles in neuronal reactions to varying energy requirements in health and disease. In Alzheimer’s disease (AD), mitochondria undergo excessive fission and become less motile. The mechanisms leading to these alterations are not completely clear. Here, we show that collapsin response mediator protein 2 (CRMP2) is hyperphosphorylated in AD and that is accompanied by a decreased interaction of CRMP2 with Drp1, Miro 2, and Mitofusin 2, which are proteins involved in regulating mitochondrial morphology and motility. CRMP2 was hyperphosphorylated in postmortem brain tissues of AD patients, in brain lysates, and in cultured cortical neurons from the double transgenic APP/PS1 mice, an AD mouse model. CRMP2 hyperphosphorylation and dissociation from its binding partners correlated with increased Drp1 recruitment to mitochondria, augmented mitochondrial fragmentation, and reduced mitochondrial motility. (S)-lacosamide ((S)-LCM), a small molecule that binds to CRMP2, decreased its phosphorylation at Ser 522 and Thr 509/514, and restored CRMP2′s interaction with Miro 2, Drp1, and Mitofusin 2. This was paralleled by decreased Drp1 recruitment to mitochondria, diminished mitochondrial fragmentation, and improved motility of the organelles. Additionally, (S)-LCM-protected cultured cortical AD neurons from cell death. Thus, our data suggest that CRMP2, in a phosphorylation-dependent manner, participates in the regulation of mitochondrial morphology and motility, and modulates neuronal survival in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill Drive, Medical Science Building, Room 362, Indianapolis, IN 46202, USA.
- Department of Molecular Pathobiology, New York University, New York, NY 10010, USA.
- College of Dentistry, NYU Pain Research Center, New York University, New York, NY 10010, USA.
- Department of Neuroscience and Physiology and Neuroscience Institute, School of Medicine, New York University, New York, NY 10010, USA.
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
ORCID-Profile: Rajesh Khanna
Förderung
- NIDA NIH HHS
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Brustovetsky, T., Khanna, R., & Brustovetsky, N. (2023). CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer’s Disease. Cells. https://doi.org/10.3390/cells12091287
Vancouver
Brustovetsky T, Khanna R, Brustovetsky N. CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer’s Disease. Cells. 2023. doi:10.3390/cells12091287
BibTeX
@article{Brustovetsky2023,
author = {Brustovetsky, Tatiana and Khanna, Rajesh and Brustovetsky, Nickolay},
title = {CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer’s Disease},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12091287}
}
EUVIMED